Biogen Inc (BIIB)

272.94
NASDAQ : Health Care
Prev Close 272.46
Day Low/High 271.62 / 274.90
52 Wk Low/High 223.02 / 333.65
Avg Volume 1.67M
Exchange NASDAQ
Shares Outstanding 215.95M
Market Cap 58.84B
EPS 17.00
P/E Ratio 16.09
Div & Yield N.A. (N.A)

Latest News

Biogen Highlights Advances From Its Neurology Research Programs And Portfolio Of Innovative Medicines At AAN Congress

Biogen Highlights Advances From Its Neurology Research Programs And Portfolio Of Innovative Medicines At AAN Congress

Biogen (NASDAQ: BIIB) will present data from its portfolio of treatments and investigational therapies for people with serious neurological and neurodegenerative diseases at the 69th annual meeting of the American...

Biotech Movers: Synergy, Biogen, Insys

Biotech Movers: Synergy, Biogen, Insys

Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Biogen Licenses Phase 2 Anti-Tau Antibody From Bristol-Myers Squibb

Biogen Licenses Phase 2 Anti-Tau Antibody From Bristol-Myers Squibb

Biogen (NASDAQ:BIIB) today announced an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), from...

Why Biotech Investors Should Worry When Their Stocks Turn Boring

Why Biotech Investors Should Worry When Their Stocks Turn Boring

Investors have turned away from biotech at a time when the sector is normally humming with presentations of new clinical data at springtime medical meetings.

Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)

Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)

In the short term, all that matters in the market is what someone is willing to pay, says Jim Cramer.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.

Biogen To Present Data At The 13th International Conference On Alzheimer's And Parkinson's Diseases

Biogen To Present Data At The 13th International Conference On Alzheimer's And Parkinson's Diseases

Biogen (NASDAQ: BIIB) will present data from its Alzheimer's and Parkinson's disease programs at the 13 th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) in Vienna, Austria March 29 -...

Biogen To Report First Quarter 2017 Financial Results On April 25, 2017

Biogen To Report First Quarter 2017 Financial Results On April 25, 2017

Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2017 financial results on Tuesday, April 25, 2017, before the financial markets open.

Week Ahead: Financials, Health Care on Edge as Obamacare Escapes GOP Axe

Week Ahead: Financials, Health Care on Edge as Obamacare Escapes GOP Axe

Wall Street could be in for a rocky week in the wake of the Republicans' failure to repeal and replace Obamacare as promised.

European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details

European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details

European stocks drifted lower Monday following a holiday-thinned trading session in Asia as investors prepare for key inflation and private sector activity data later in the week.

European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade

European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade

European stocks are expected to open mixed Monday following a holiday-thinned trading session in Asia as investors prepare for key inflation and private sector activity data later in the week.

Week in Review: Stocks Post Small Gains After Fed Pulls Trigger on Third Hike Since Crisis

Week in Review: Stocks Post Small Gains After Fed Pulls Trigger on Third Hike Since Crisis

Wall Street ends with modest gains in a week in which the Federal Reserve decided to pull the trigger on an interest rate hike.

Dow, S&P 500 Decline as Health Care Losses Counter Gains

Dow, S&P 500 Decline as Health Care Losses Counter Gains

Wall Street ends a jampacked week little changed as a selloff in health care stocks counters broad gains elsewhere.

Broad Gains Overshadow Health Care Losses to Boost Wall Street

Broad Gains Overshadow Health Care Losses to Boost Wall Street

Stocks rise on Friday even as a selloff in health care extends into its second day.

Midday Report: Amgen Leads Health Care Lower; U.S. Stocks Fall

Midday Report: Amgen Leads Health Care Lower; U.S. Stocks Fall

Stocks creep lower on Friday as a selloff in health care extends into its second day, this time led by Amgen shares.

Stocks Creep Lower as Health Care Selloff Extends Into Day 2

Stocks Creep Lower as Health Care Selloff Extends Into Day 2

Stocks creep lower on Friday as a selloff in health care extends into its second day.

Dow, S&P 500 Retreat From Rally as Health Care Selloff Interrupts Fed Boost

Dow, S&P 500 Retreat From Rally as Health Care Selloff Interrupts Fed Boost

Investor sentiment soured on Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.

S&P 500 Trades Lower as Health Care Sells Off, Crude Fluctuates

S&P 500 Trades Lower as Health Care Sells Off, Crude Fluctuates

Stocks are slightly lower by early afternoon Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.

Cramer: Confusion Reigns in This Market

Cramer: Confusion Reigns in This Market

Many want to undo what's been done, but not enough to send the market down.

Midday Report: Biogen Weighs on Health Care Stocks; U.S. Markets Fall

Midday Report: Biogen Weighs on Health Care Stocks; U.S. Markets Fall

Stocks give back earlier gains as a selloff in health care overshadows the Federal Reserve's decision a day earlier to raise interest rates.

Stocks Extend Declines as Biogen Leads Health Care Selloff

Stocks Extend Declines as Biogen Leads Health Care Selloff

Early morning gains quickly evaporate on Thursday as a selloff in health care overshadows the Federal Reserve's decision a day earlier to raise interest rates.

Analysts' Actions -- Liberty Global, RPM International, TJX, Biogen and More

Analysts' Actions -- Liberty Global, RPM International, TJX, Biogen and More

Here are Thursday's top research calls, including upgrades of TJX Companies, Liberty Global and RPM International, and downgrades of Biogen, Sunworks and Tredegar.

Biogen Appoints Anirvan Ghosh Senior Vice President, Research And Early Development

Biogen Appoints Anirvan Ghosh Senior Vice President, Research And Early Development

Biogen (NASDAQ:BIIB) today announced the appointment of Anirvan Ghosh, Ph.

Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears

Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears

Despite all the prior failures and blowups, an Alzheimer's drug study -- no matter how unlikely to succeed -- remains an irresistible lure for some investors.

Celgene's Deep Pipeline Can Reassure Investors

Celgene's Deep Pipeline Can Reassure Investors

This biotech company is trading at a bargain compared to its peer group.

Biogen To Present At The Cowen & Company 37th Annual Health Care Conference

Biogen To Present At The Cowen & Company 37th Annual Health Care Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Cowen & Company 37 th Annual Health Care Conference.

After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B

After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B

Perrigo also said it will review its API business, which provides differentiated active pharmaceutical ingredients and finished dosage forms for the branded and generic industries.